A literature review on the parvovirus B19 infection in sickle cell anemia and β-thalassemia patients

Table 2 Parvovirus B19 prevalence in SCD patients

First Author	Country	Year	Sample size		Mean age (year)	Sex^a		IgG prevalence (%)		IgM prevalence (%)		Genotype	PCR prevalence		Method	Study Design	Ref.
First Author	Country	Year	Case	Control	Mean age (year)	Male	Female	Case	Control	Case	Control	Genotype	Case	Control	Method	Study Design	Ref.
Slavov	Brazil	2012	144	100	19.22 years (range: 1–72 years)	48.6%	51.4%	65.9	60	–		1A	19.4	1	Sequencing, ELISA, qPCR,	CS	[20]
Ayolabi	Nigeria	2017	68	25	1–35 years	44	49	–		15	16	–			ELISA	CS	[23]
Obeid	Saudi Arabia	2011	138	56	28	77	61	37.6	39.3	2.9		–	4		ELISA, real-time PCR	CS	[24]
Makhlouf	Egypt	2015	100	60	7.8 ± 1.7	50	50	44	10	30	0	–	54	3.3	Nested-PCR, ELISA	CS	[25]
Hankins	USA	2016	330		7.6 (range 0.4–18)	–		38		–		–	–		ELISA	CS	[26]
Diallo	Africa	2011	163	163	1–45 years	91	72	64.8	48.4	25	6.1	–	–		ELISA	CC	[27]
Iwalokun	Nigeria	2013	73	81	16.9 ± 0.7	40	33	61.6	64.2	17.8	11.1	–	11.1		ELISA, PCR	CS	[28]

^aSome studies reported the number of male/Female and another reported percentage
CC case-control, PCR polymerase chain reaction, CS cross-sectional, ELISA enzyme-linked immunosorbent assay, qPCR quantitative PCR

ISSN: 1349-4147